|Articles|February 13, 2023
AstraZeneca Looks for Growth With New Drugs as COVID Sales Wane
Advertisement
Per Reuters, Astrazeneca CEO Pascal Soriot announced that the company is on track to deliver at least 15 new medicines this decade and expect to start at least 30 new late-stage clinical trials in 2023.
AstraZeneca also predicts a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth, despite ongoing drug price pressure.
The CEO stated that they are "very much on track to deliver [their] industry-leading growth ambitions for 2025, but also beyond until 2030." Despite facing higher costs due to the ongoing pandemic and the war in Ukraine, AstraZeneca's operating profit margins have risen from 27% in 2021 to 30% in 2022 and are expected to continue to improve steadily.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
2
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
3
Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms
4
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
5